(Q44879852)

English

Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 December 2017

Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group (English)

1 reference

Europe PubMed Central

7 December 2017

endometrial carcinoma

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

author name string

Russell J Schilder

1

1 reference

Europe PubMed Central

7 December 2017

John A Blessing

2

1 reference

Europe PubMed Central

7 December 2017

Michael L Pearl

3

1 reference

Europe PubMed Central

7 December 2017

Peter G Rose

4

1 reference

Europe PubMed Central

7 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 August 2004

1 reference

Europe PubMed Central

7 December 2017

Investigational New Drugs

1 reference

Europe PubMed Central

7 December 2017

22

1 reference

Europe PubMed Central

7 December 2017

3

1 reference

Europe PubMed Central

7 December 2017

343-349

1 reference

Europe PubMed Central

7 December 2017

https://scigraph.springernature.com/pub.10.1023/b:drug.0000026262.77502.31

0 references

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical and pharmacokinetic trial of irofulven

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2003.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I population pharmacokinetics of irofulven

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Letter: Creatinine clearance: bedside estimate.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discovery and development of sesquiterpenoid derived hydroxymethylacylfulvene: a new anticancer drug

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF)

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15122083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1023/B:DRUG.0000026262.77502.31

1 reference

Europe PubMed Central

7 December 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

7 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44879852&oldid=2055080784"